Results 261 to 270 of about 109,213 (308)

Basic Principles of Antisense Drug Discovery

2007
It has been nearly 30 years since the first reports of inhibition of gene expression using an antisense oligonucleotide (ASO) [1]. Although many technological hurdles remained to be solved, the potential of antisense inhibitors for therapeutic applications was clearly apparent at that time.
Andrew Watt, Susan Freier
openaire   +2 more sources

Huntington’s antisense drug marches into clinic

Nature Biotechnology, 2020
Prospects for agents aimed at stopping neuronal loss brighten, driven by new mechanistic understanding.
openaire   +1 more source

Molecular mechanisms of action of antisense drugs

Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1999
Given the progress reported during the past decade, a wide range of chemical modifications may be incorporated into potential antisense drugs. These modifications may influence all the properties of these molecules, including mechanism of action. DNA-like antisense drugs have been shown to serve as substrates when bound to target RNAs for RNase Hs ...
openaire   +2 more sources

[Current status of antisense drugs].

Sheng li ke xue jin zhan [Progress in physiology], 2003
The antisense was first imagined as the therapeutic drug at the end of 1970. After 20 years the antisense drugs have been hitting into the market from laboratory and clinical research. Antisense captures general attention with their promise of rational drug design and exquisite specification.
openaire   +1 more source

Pfizer buys into Akcea antisense drug

C&EN Global Enterprise, 2019
Pfizer is paying $250 million to license an antisense therapy in Phase II studies to treat diabetes, hypertriglyceridemia, and nonalcoholic fatty liver disease. The sellers are Ionis Pharmaceuticals and its affiliate Akcea Therapeutics. AKCEA-ANGPTL3-LRx lowers levels of a liver protein, angiopoietin-like 3 (ANGPTL3), that helps control triglycerides ...
openaire   +1 more source

Current concepts in antisense drug design

Journal of Medicinal Chemistry, 1993
J F, Milligan, M D, Matteucci, J C, Martin   +2 more
openaire   +2 more sources

Dynacure launches with Ionis antisense drug

C&EN Global Enterprise, 2018
Dynacure, a small start-up in Strasbourg, France, has raised $55 million to develop nucleic acid-based drugs for rare genetic muscle diseases. Its first program will test an antisense oligonucleotide licensed from Ionis Pharmaceuticals to treat centronuclear myopathy (CNM), a condition that causes muscle weakness and wasting.
openaire   +1 more source

Cancer epigenetics in clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Veronica Davalos, Manel Esteller
exaly  

Antisense Drug Technology

Journal of Controlled Release, 2003
openaire   +1 more source

Modern developments in germline pharmacogenomics for oncology prescribing

Ca-A Cancer Journal for Clinicians, 2022
Natalie M Reizine, Peter H O'donnell
exaly